Thymostimulin in advanced hepatocellular carcinoma: A phase II trial

BMC Cancer

Table 2 Reasons for termination of treatment and cause of death

	Termination of treatment (n = 44)
Death within 6 weeks of study entry^§	5
Tumor progression	29
Hepatic failure with stable disease^§	5
Other*	3
CR (one patient with concomitant RFTA)	2

* pneumonia after femur fracture, ventricular fibrillation and haemorrhage during surgical resection
^§ cause of death hepatic failure without proven tumor progress

ISSN: 1471-2407